Curative Biotechnology, Inc. (CUBT)

OTCMKTS · Delayed Price · Currency is USD
0.0087
+0.0008 (10.13%)
Mar 6, 2026, 2:35 PM EST
-32.03%
Market Cap 9.33M
Revenue (ttm) n/a
Net Income (ttm) -2.84M
Shares Out 1.07B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,000
Average Volume 84,385
Open 0.0077
Previous Close 0.0079
Day's Range 0.0077 - 0.0087
52-Week Range 0.0030 - 0.0288
Beta 1.41
RSI 65.18
Earnings Date Apr 15, 2026

About Curative Biotechnology

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol CUBT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.